Text this: A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost

             ___      ______   _    _     ____    
  ____      / _ \\   /_____// | || | ||  |  _ \\  
 |    \\   / //\ \\  `____ `  | || | ||  | |_| || 
 | [] ||  |  ___  || /___//   | \\_/ ||  | .  //  
 |  __//  |_||  |_|| `__ `     \____//   |_|\_\\  
 |_|`-`   `-`   `-`  /_//       `---`    `-` --`  
 `-`                 `-`